Reuters logo
3 个月前
BRIEF-Esperion reports Q1 net loss per common share $1.80
2017年5月4日 / 晚上8点56分 / 3 个月前

BRIEF-Esperion reports Q1 net loss per common share $1.80

1 分钟阅读

May 4 (Reuters) - Esperion Therapeutics Inc

* Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results

* Esperion Therapeutics Inc - esperion expects full-year 2017 net cash used in operating activities to be approximately $125 to $135 million

* Qtrly net loss per common share $1.80 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below